ES2090393T3 - Beta-lactamas. - Google Patents

Beta-lactamas.

Info

Publication number
ES2090393T3
ES2090393T3 ES92105263T ES92105263T ES2090393T3 ES 2090393 T3 ES2090393 T3 ES 2090393T3 ES 92105263 T ES92105263 T ES 92105263T ES 92105263 T ES92105263 T ES 92105263T ES 2090393 T3 ES2090393 T3 ES 2090393T3
Authority
ES
Spain
Prior art keywords
sulphur
beta
oxygen
denotes
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92105263T
Other languages
English (en)
Inventor
Robert Charnas
Klaus Gubernator
Ingrid Heinze
Christian Hubschwerlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2090393T3 publication Critical patent/ES2090393T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

BETA SE DESCRIBEN (BETA) EN LA QUE R EQUIVALE A UN ALCOXICARBONILO, ALCOXICARBONILAMINO BAJOS, EL RESTO ACILO DE UN AMINOACIDO O O (BETA) O UN RESTO DE LA FORMULA GENERAL Q ANILLO DE 3 AZUFRE Y/U OXIGENO, EN TODO CASO UNIDO A UN ANILLO NO CONDENSADO, X EQUIVALE A UN ENLACE DIRECTO O A UN SEPARADOR ("SPACER") LINEAL QUE CONTIENE CARBONO, NITROGENO, OXIGENO Y/O AZUFRE, CON HASTA CON 6 ATOMOS, DE LOS QUE PUEDEN SER HASTA 2 ATOMOS, ATOMOS DE NITROGENO, Y 1 ATOMO DE OXIGENO O AZUFRE, E Y EQUIVALE A UNO DE LOS GRUPOS COMO ESLABON FINAL NO CONTENGA AZUFRE NI CARBONILO) DONDE, ADEMAS, R1 EQUIVALE A HIDROGENO, HALOGENO, CARBAMOILOXI, ALCANOILOXI BAJO O UN GRUPO DE FORMULA CA UN GRUPO DE 5 NITROGENO, AZUFRE Y/U OXIGENO Y R2 REPRESENTA EL GRUPO SULFURICO QUIVALE A HIDROGENO O UN RESTO UTILIZABLE EN 3 POSICIONES DE ANTIBIOTICO DE CEFALOSPORINA, Y DONDE ADEMAS R3 REPRESENTA HIDROGENO, O R1 Y R3 JUNTOS FORMAN UN GRUPO DE LA FORMULA GENERAL (C) DONDE RA EQUIVALE A UNO DE LOS GRUPOS, - CORB (C1) OCOORC (C2) RB EQUIVALE A UN ALCOXI O AMINO BAJO, RC ALQUILO BAJO, FENILO O AMINO, RD Y RE CADA UNO HIDROGENO O ALQUILO BAJO, O JUNTO CON EL ATOMO N FORMAN UN GRUPO DE 5 RO N NO O AZUFRE Y HET UN GRUPO HETEROAROMATICO DE 5 CONTENIENDO NITROGENO, AZUFRE Y/U OXIGENO, Y SALES DE ESTOS COMPUESTOS UTILIZABLES EN FARMACIA. ADEMAS TAMBIEN EL PROCEDIMIENTO DE OBTENCION DE ESTA (BETA) TOS INTERMEDIOS SURGIDOS. ADEMAS LOS MEDICAMENTOS CORRESPONDIENTES. LOS PRODUCTOS POSEEN PROPIEDADES INHIBIDORAS DE LA (BETA) AUSADAS POR LA (BETA) ICOS BETA-LACTAMICOS.
ES92105263T 1991-04-11 1992-03-27 Beta-lactamas. Expired - Lifetime ES2090393T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH108391 1991-04-11
CH42992 1992-02-13

Publications (1)

Publication Number Publication Date
ES2090393T3 true ES2090393T3 (es) 1996-10-16

Family

ID=25684556

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92105263T Expired - Lifetime ES2090393T3 (es) 1991-04-11 1992-03-27 Beta-lactamas.

Country Status (12)

Country Link
US (3) US6566355B1 (es)
EP (1) EP0508234B1 (es)
JP (1) JP3553983B2 (es)
AT (1) ATE140702T1 (es)
AU (1) AU649799B2 (es)
CA (1) CA2064945A1 (es)
DE (1) DE59206796D1 (es)
DK (1) DK0508234T3 (es)
ES (1) ES2090393T3 (es)
GR (1) GR3021434T3 (es)
IE (1) IE76147B1 (es)
NZ (1) NZ242259A (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5016345A (en) * 1989-08-17 1991-05-21 Mecanismos Auxiliares Industriales, S.A. Apparatus for assembling wire harnesses
ES2090393T3 (es) * 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
CA2143519A1 (en) * 1994-03-11 1995-09-12 Markus Bohringer Beta-lactams
DE4437137A1 (de) * 1994-10-18 1996-04-25 Hoechst Schering Agrevo Gmbh Substituierte Cycloalkylamino- und -alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
US5750681A (en) * 1995-06-19 1998-05-12 University Of Notre Dame Du Lac Bicyclic beta-lactams and process therefor
TW358097B (en) 1996-05-24 1999-05-11 Hoffmann La Roche Beta-lactams and their process and pharmaceutical compositions
MX338505B (es) * 2005-12-07 2016-04-20 Basilea Pharmaceutica Ag Combinaciones utiles de antibioticos de monobactama con inhibidores de beta-lactamasa.
AU2012233003B2 (en) * 2005-12-07 2014-12-18 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
AU2007300531A1 (en) * 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
DK2197881T3 (da) * 2007-09-17 2013-06-24 Basilea Pharmaceutica Ag Fremgangsmåde til fremstillingen af brokoblede monolactam-mellemprodukter
DK2666774T3 (en) 2008-01-18 2015-03-23 Merck Sharp & Dohme Beta-lactamase INHIBITORS
AU2011263417B2 (en) * 2010-06-11 2014-03-27 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
CA2911544A1 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Preparation of tert-butyl 4-((1r,2s,5r)-6-(benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate
CN103554112B (zh) * 2013-11-07 2016-04-13 中国科学院昆明植物研究所 顺式稠环的β-内酰胺化合物的合成方法
WO2015112441A1 (en) 2014-01-22 2015-07-30 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
EP3139918B1 (en) 2014-05-09 2019-12-25 Merck Sharp & Dohme Corp. Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
WO2016206101A1 (en) 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
EP3654968B1 (en) 2017-07-17 2023-08-16 Merck Sharp & Dohme LLC Metallo-beta-lactamase inhibitors and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076758B1 (en) * 1981-10-05 1987-01-07 E.R. Squibb & Sons, Inc. 4-ether derivatives of 2-azetidinone-1-sulfonic acids
DE3366497D1 (en) * 1982-01-22 1986-11-06 Beecham Group Plc Antibacterial agents, their preparation and use
WO1987004429A1 (en) * 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
JPH02202891A (ja) 1989-02-01 1990-08-10 Sanraku Inc β―ラクタム化合物とそれらの製法
ES2090393T3 (es) * 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
CA2143519A1 (en) * 1994-03-11 1995-09-12 Markus Bohringer Beta-lactams

Also Published As

Publication number Publication date
CA2064945A1 (en) 1992-10-12
US5510343A (en) 1996-04-23
DE59206796D1 (de) 1996-08-29
JP3553983B2 (ja) 2004-08-11
EP0508234B1 (de) 1996-07-24
AU1406692A (en) 1992-10-15
IE921170A1 (en) 1992-10-21
DK0508234T3 (da) 1996-10-28
GR3021434T3 (en) 1997-01-31
EP0508234A2 (de) 1992-10-14
IE76147B1 (en) 1997-10-08
US6566355B1 (en) 2003-05-20
EP0508234A3 (en) 1993-03-10
US5698577A (en) 1997-12-16
ATE140702T1 (de) 1996-08-15
AU649799B2 (en) 1994-06-02
JPH05186468A (ja) 1993-07-27
NZ242259A (en) 1994-07-26

Similar Documents

Publication Publication Date Title
ATE140702T1 (de) Beta-lactame
DE69331089T2 (de) Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
FI933357A0 (fi) Foerfarande foer framstaellning av benzamider
IL103875A0 (en) Piperazinyl-and piperidinyl-cyclohexanol derivatives and pharmaceutical compositions containing the same
KR940005568A (ko) 1-아미노아세트아미도피롤, 1-아미노 아세트아미도-2-(치환된)피롤 및 관련 화합물
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
ATE110081T1 (de) Cephalosporinderivate mit in der lage 3 eine thioalkylthiogruppe.
AU7130194A (en) N-(piperidinyl-1-alkyl)-substituted cyclohexane carboxylic acid amides as 5-ht1a receptor antagonists
AU4872793A (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them
AU572994B2 (en) Cephalosporin derivatives
DE69625795D1 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
NO891608L (no) Heterotetracykliske laktamderivater.
AU3165389A (en) Heterocyclic substituted 5,7-dihydropyrrolo (3,2-f)- benzoxazol-6-ones, processes for the preparation thereof and pharmaceutical compositions containing them
DE3374783D1 (en) Beta-lactam antibiotics, process for their preparation and preparations containing them
ES1024995U (es) "espejo retrovisor para vehiculos automoviles"
TH5599EX (th) อนุพันธุ์ของคาร์บาโมอิลลอกซีไธโอฟีน
FI900007A (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-aminoalkyl-b-karbolinderivat.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 508234

Country of ref document: ES

FG2A Definitive protection

Ref document number: 508234

Country of ref document: ES